Media headlines about Dova Pharmaceuticals (NASDAQ:DOVA) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dova Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.2126675865421 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Several research firms recently commented on DOVA. Jefferies Group LLC began coverage on Dova Pharmaceuticals in a research note on Monday, July 24th. They issued a “buy” rating and a $30.00 price objective for the company. J P Morgan Chase & Co began coverage on Dova Pharmaceuticals in a research note on Monday, July 24th. They issued an “overweight” rating and a $35.00 price objective for the company. Finally, Leerink Swann began coverage on Dova Pharmaceuticals in a research note on Monday, July 24th. They issued a “market perform” rating and a $24.00 price objective for the company.

Shares of Dova Pharmaceuticals (DOVA) opened at 26.81 on Tuesday. The stock’s market capitalization is $687.73 million. Dova Pharmaceuticals has a one year low of $18.18 and a one year high of $28.24. The firm has a 50-day moving average price of $23.58 and a 200 day moving average price of $23.04.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.08. On average, equities analysts expect that Dova Pharmaceuticals will post ($1.40) EPS for the current fiscal year.

In related news, Director Paul B. Manning purchased 25,870 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was bought at an average cost of $22.30 per share, with a total value of $576,901.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steven M. Goldman purchased 72,000 shares of the business’s stock in a transaction dated Wednesday, July 5th. The stock was bought at an average cost of $17.94 per share, with a total value of $1,291,680.00. Following the completion of the acquisition, the director now owns 42,000 shares of the company’s stock, valued at $753,480. The disclosure for this purchase can be found here. Over the last three months, insiders bought 147,839 shares of company stock valued at $2,823,538.

TRADEMARK VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/12/dova-pharmaceuticals-dova-earning-somewhat-favorable-news-coverage-report-shows.html.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Insider Buying and Selling by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Stock Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.